# Pembrolizumab

## Keytruda inj 100mg/4mL

| TAH Drug Code      | [IKEY1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKEY1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1. Melanoma 2. Non-small cell lung cancer 3. Classical Hodgkin’s lymphoma 4. Squamous cell carcinoma of the head and neck 5. Urothelial carcinoma 6. Gastric cancer 7. Primary mediastinal B-cell lymphoma 8. Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers 9. Microsatellite instability-high or mismatch repair deficient colorectal cancer 10. Hepatocellular carcinoma 11. Biliary tract carcinoma 12. Cervical cancer 13. Renal cell carcinoma 14. Endometrial cancer 15. Esophageal cancer 16. Triple-negative breast cancer (TNBC) 17. Tumor mutational burden-high (TMB-H) cancers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | [Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months. [Classical Hodgkin Lymphoma (cHL)， Head and Neck Squamous Cell Cancer (HNSCC)， Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to pembrolizumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Hypertension (24-67%)， Alopecia (34-61%)， Pruritus (11-41%)， Rash (1.4-71%)， Hypercholesterolemia (Non-small cell lung cancer， 20%)， Hyperglycemia (40-48%)， Hypertriglyceridemia (23-25%)， Hypoalbuminemia (32-34%)， Hyponatremia (10-38%)， Weight decreased (10-34%)， Constipation (12-42%)， Decrease in appetite (16-44%)， Diarrhea (12-62%)， Nausea (11-67%)， Leukopenia (24%)， Thrombocytopenia (35%)， Alkaline phosphatase above reference range (Non-small cell lung cancer， 26%)， Aspartate aminotransferase serum level above reference range (20-24%)， Arthralgia (10-31%)， Disorder of musculoskeletal system (53-58%)， Musculoskeletal pain (16-41%)， Neuropathy (1-67%)， Proteinuria (29-30%)， Urinary tract infectious disease (11-32%)， Cough (11-26%)， Dyspnea (10-23%)， Fatigue (20-70%). Serious: Myocardial infarction (Serious: 2%)， Myocardial ischemia (2%)， Myocarditis (0.5-1.4%)， Pericarditis (4%)， Right ventricular dysfunction， Vasculitis， Vasculitis， Drug reaction with eosinophilia and systemic symptoms， Hand-foot syndrome due to cytotoxic therapy (23-28%)， Stevens-Johnson syndrome， Stevens Johnson syndrome AND toxic epidermal necrolysis overlap， Toxic epidermal necrolysis， Adrenal insufficiency (0.8%)， Hyperthyroidism (3-12%)， Hypoparathyroidism， Hypophysitis (0.6%)， Hypothyroidism (8-67%)， Thyroiditis (0.6-2%)， Type 1 diabetes mellitus (0.2%)， Colitis (1.7%)， Duodenitis， Gastritis， Gastrointestinal obstruction， Malignant， Gastrointestinal perforation， Lower gastrointestinal hemorrhage， Pancreatitis， Anemia， Grade 3 or 4 (2-8%)， Aplastic anemia， Febrile neutropenia (1.4%)， Hemolytic anemia， Hemophagocytic lymphohistiocytosis， Hemorrhage (19-27%)， Immune thrombocytopenia， Venous thromboembolism， Hepatitis (0.7-2.9%)， Hepatotoxicity (14-39%)， Veno-occlusive disease of the liver (9%)， Anaphylaxis， Graft versus host disease (26%)， Histiocytic necrotizing lymphadenitis， Hypersensitivity reaction (4.1%)， Sarcoidosis， Systemic inflammatory response syndrome， Transplanted organ rejection， Vogt-Koyanagi-Harada disease， Eaton-Lambert syndrome， Myasthenia gravis (2.5%)， Myositis (1-3.3%)， Polymyalgia rheumatica， Polymyositis， Rhabdomyolysis， Confusional state (Head and neck cancer， 2% or more)， Demyelination of spinal cord， Encephalitis， Guillain-Barre syndrome， Meningitis， Myelitis (0.5%)， Nerve palsy， Iritis， Myasthenia gravis， Ocular， Optic neuritis， Uveitis (Up to 1.4%)， Visual impairment， Acute renal failure (13-21%)， Nephritis， Renal failure， Sepsis due to urinary tract infection， Pleural effusion (2% or more)， Pneumonia (2% or more)， Pneumonitis (2-11%)， Pulmonary embolism (2%)， Pulmonary hemorrhage， Respiratory failure (2% or more)， Cardiorespiratory arrest， Disorder characterized by fever， Steroid-requiring， Fever (10-28%)， Infusion reaction (0.2%)， Infusion reaction (0.2-9%)， Multiple organ failure， Sepsis (Up to 10%) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pembrolizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

